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AbstrACt
Objectives To quantify the risk of overdiagnosis 
associated with prostate cancer screening in Australia 
using a novel lifetime risk approach.
Design Modelling and validation of the lifetime risk 
method using publicly available population data.
setting Opportunistic screening for prostate cancer in the 
Australian population.
Participants Australian male population (1982–2012).
Interventions Prostate-specific antigen testing for 
prostate cancer screening.
Primary and secondary outcome measures Primary: 
lifetime risk of overdiagnosis in 2012 (excess lifetime 
cancer risk adjusted for changing competing mortality); 
Secondary: lifetime risk of prostate cancer diagnosis 
(unadjusted and adjusted for competing mortality); Excess 
lifetime risk of prostate cancer diagnosis (for all years 
subsequent to 1982).
results The lifetime risk of being diagnosed with prostate 
cancer increased from 6.1% in 1982 (1 in 17) to 19.6% 
in 2012 (1 in 5). Using 2012 competing mortality rates, 
the lifetime risk in 1982 was 11.5% (95% CI 11.0% to 
12.0%). The excess lifetime risk of prostate cancer in 2012 
(adjusted for changing competing mortality) was 8.2% 
(95% CI 7.6% to 8.7%) (1 in 13). This corresponds to 41% 
of prostate cancers being overdiagnosed.
Conclusions Our estimated rate of overdiagnosis is in 
agreement with estimates using other methods. This 
method may be used without the need to adjust for lead 
times. If annual (cross-sectional) data are used, then it 
may give valid estimates of overdiagnosis once screening 
has been established long enough for the benefits from the 
early detection of non-overdiagnosed cancer at a younger 
age to be realised in older age groups.
IntrODuCtIOn 
After the commencement of population 
cancer screening, a spike in the apparent inci-
dence of the cancer is expected. These excess 
cancers may reflect both (1) detection of 
cancers that otherwise would have progressed 
to symptomatic disease (non-overdiag-
nosed cancers; potential beneficial effect of 
screening) and (2) detection of cancers that 
otherwise would not have become symp-
tomatic (overdiagnosed cancers; potential 
harmful effect of screening). Histopathology 
assessment of screen-detected abnormalities 
may result in overdiagnosis due to imperfect 
discrimination between biologically benign 
lesions and lesions that would progress 
towards clinical malignancy if left untreated.1 
As there is no direct way to predict with 
certainty which individual cancers will prog-
ress without treatment and which will not, we 
must use indirect population-based methods 
to estimate the proportion of cancers that are 
likely to have been overdiagnosed.
Estimations of the extent of overdiagnosis 
need to account for lead time, the time 
strengths and limitations of this study
 ► We describe a new method which may be easily ap-
plied using freely available statistical software and 
publicly available administrative datasets.
 ► The method may be used in combination with other 
methods to triangulate the likely extent of cancer 
overdiagnosis in populations where data from ran-
domised controlled trials are not available.
 ► Unlike other methods that use observational data to 
estimate overdiagnosis, there is no need to adjust 
for the lead time advancement in the time of diag-
nosis for non-overdiagnosed cancers.
 ► However, when using cross-sectional data for this 
method, screening needs to be established for a 
period at least as long as the average lead time of 
non-overdiagnosed cancers.
 ► The method also assumes that there are no underly-
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between when a non-overdiagnosed cancer is diagnosed 
due to early detection through screening, and when it 
would have been detected clinically. Compared with the 
unscreened group, lead time causes an increase in the 
annual cancer incidence during screening and a compen-
satory drop in the annual incidence after screening ends. 
This occurs until the end of the longest lead time of a 
non-overdiagnosed cancer.2 Current methods to quan-
tify cancer overdiagnosis from screening require esti-
mates of lead time(s).2–4 However, lead time estimation 
is statistically problematic,5 as assumptions may result 
in either overestimation of the maximum lead time and 
underestimation of overdiagnosis6–8 or underestimation 
of the maximum lead time and overestimation of overdi-
agnosis.9 10 Hence, methods that sidestep explicit assump-
tions about the lead time would be useful.
LIfetIme rIsk Of CAnCer In trIALs
One alternative method that would not require assump-
tions about the lead time distribution for progressive 
cancers is a post-trial study after a screening randomised 
controlled trial (RCT), with follow-up continuing until 
all trial participants have died. We could then calcu-
late the lifetime incidence of a cancer diagnosis for the 
screened and unscreened trial arms: any excess incidence 
in the screened arm would be attributable to overdiag-
nosis. This is essentially the excess cumulative incidence 
method after a stop-screen trial4 11–13 using an extreme 
follow-up time to ensure that the longest possible lead 
time for any screen-detected cancers is captured. Chal-
lenges to this method include the long time frame, the 
need for collaboration with trialists to access individual 
patient data for post-trial linkage to cancer registries and 
mortality data, and losses to follow-up due to emigration 
or other causes. There may also be issues of reduced 
applicability of overdiagnosis estimates from older trials 
to the present situation, for example, due to changes in 
screening and/or diagnostic test thresholds and tech-
nologies, as well as changes in the effectiveness of treat-
ments that may change the effectiveness of screening and 
changes in competing mortality risk. However, the most 
important challenge may be post-trial screening in both 
the intervention and control arms—if this is measured 
then it may be possible to adjust for this statistically, but 
all post-trial studies to date have only measured screening 
during the within trial period.
usIng POPuLAtIOn DAtA tO estImAte LIfetIme rIsk Of 
CAnCer
An observational alternative to estimating lifetime risk of 
a cancer in trials is to apply life table and related methods 
to annual population data. These methods are currently 
used by cancer agencies worldwide to calculate lifetime 
risks of being diagnosed with cancer and of dying from 
cancer, which are commonly framed in terms of a ‘one 
in x’ chance to communicate the risk in a more readily 
understood way (eg, women have a one in eight chances 
of being diagnosed with breast cancer in their lifetime).14 
Life table methods commonly use cross-sectional age-spe-
cific cancer incidence and mortality rates, together with 
all-cause mortality rates, to estimate lifetime and age-spe-
cific conditional probabilities of developing a particular 
cancer in a hypothetical cohort who experience each 
age-specific rate over their lifetimes.
Statistical methods have been developed to estimate 
these probabilities where rates are reported per person-
years alive (including people who are living with a cancer 
diagnosis; this is how these data are commonly reported 
in cancer registries) and to comprehensively account for 
competing risks.15 This method is used in the DevCan soft-
ware provided free of charge on the Surveillance, Epide-
miology, and End Results program  website,16 which we 
used in the example of prostate cancer in Australian men 
below. As well as illustrating how the life table method 
may be used to estimate lifetime risk of overdiagnosis, to 
our knowledge these results are the first estimates of the 
extent of prostate cancer overdiagnosis among Australian 
men.
usIng POPuLAtIOn DAtA tO estImAte LIfetIme rIsk Of 
OverDIAgnOsIs
If screening activities have been in place for a suffi-
ciently long time, then a comparison of lifetime risks of 
cancer diagnosis, using annual population data before 
and after the introduction of screening, may be used to 
estimate cancer overdiagnosis. However, as reductions in 
competing mortality over time can increase lifetime cancer 
risks, lifetime risks that are calculated using contempo-
raneous competing mortality rates cannot be simply 
compared. For example, decreasing competing mortality 
from cardiovascular disease may lead to increasing cancer 
risk because more people live long enough for cancers 
to present clinically. To ensure that a difference in life-
time risk is due to overdiagnosis rather than changes in 
competing mortality, we aimed to calculate the lifetime 
risk of overdiagnosis using the same competing mortality 
risk for both years before and after the introduction of 
screening.
LIfetIme rIsk Of PrOstAte CAnCer OverDIAgnOsIs 
In AustrALIAn men
In our example on prostate cancer overdiagnosis, we set 
competing mortality to the rates reported for the most 
recent calendar year (2012, ‘adjusted lifetime risk’) by 
using the age-specific prostate cancer mortality rates and 
age-specific all-cause mortality rates for 2012, while using 
the age-specific incidence rates for the index year. We 
then estimated the excess lifetime risk as the difference 
between the adjusted lifetime risk of being diagnosed 
with cancer in an index year (after screening was intro-
duced) and the adjusted lifetime risk of cancer diagnosis 
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In DevCan, the probability of getting a first cancer diag-
nosis in a specific age interval is estimated based on a 
conditional cumulative incidence function using: first 
incidence of cancer per person-years alive, rate of cancer 
deaths per person-years alive and the rate of other 
(non-cancer) deaths per person-years alive.15 17 Lifetime 
risk of overdiagnosis was calculated as a proportion of the 
(adjusted) lifetime risk in an unscreened population or 
in a screened population. In the previous literature, the 
results for the screened population have been suggested 
as the most helpful presentation.3 18 19
Prostate-specific antigen test and incidence of prostate 
cancer
The prostate-specific antigen (PSA) test, which first 
received government subsidy in Australia in 1989, is used 
to screen for prostate cancer or for post-treatment surveil-
lance. The increasing incidence of prostate cancer and 
lifetime risk of being diagnosed is thought by many to be 
due to PSA testing.20 21 Despite some decline in the rate of 
PSA screening in recent years, approximately 15%–18% 
of men in the 55–65 age group had a PSA test in 2015.22
Data
Data for age-specific prostate cancer incidence and 
mortality, and all-cause mortality were retrieved for the 
years 1982–2012 (most recent available) from Austra-
lian Cancer Database (ACD) compiled by the Australian 
Institute of Health and Welfare (AIHW) based on data 
provided by the state and territory cancer registries. By 
legislation, cancer is a notifiable disease in all Australian 
states and territories. Various institutions, such as hospi-
tals, pathology laboratories and registries of births, deaths 
and marriages, are required to report cancer cases and 
deaths to their jurisdictional cancer registry. Each registry 
will then supply incidence data annually to the AIHW. 
These data are checked, standardised and compiled into 
the ACD, the only repository of national cancer incidence 
data. The data from each of Australia’s cancer registries 
are classified by International Agency for Research on 
Cancer as ‘A’, which is the highest data quality grade 
in their scale.23 Mortality data were derived from the 
National Mortality Database, AIHW. Cause of Death Unit 
Record File data are provided to the AIHW by the Regis-
tries of Births, Deaths and Marriages and the National 
Coronial Information System and include cause of death 
coded by the Australian Bureau of Statistics. Thus, these 
are routinely collected, annual, administrative popula-
tion data.21 24 Therefore, our calculations included popu-
lations where screening is available or offered and not 
limited to just the men who actually underwent screening 
but those who were diagnosed through all means.
We used DevCan V.6.7.5 statistical software provided by 
US National Cancer Institute16 to generate life tables and 
calculate lifetime risks of developing prostate cancer for 
each calendar year. We first calculated the rates adjusting 
for contemporaneous competing mortality, and then 
calculated adjusted rates using 2012 competing mortality 
for all years. To evaluate whether screening was estab-
lished for a sufficiently long time to make the assumption 
of the method tenable, we examined temporal trends in 
PSA use for screening based on claims made to the Medi-
care Benefits Schedule (MBS). Finally, as a sensitivity anal-
ysis, we calculated excess lifetime risk using birth cohort 
(longitudinal) data rather than annual (cross-sectional) 
data.
Patient and public involvement
As this was a secondary analysis of publicly available popu-
lation data, no informed consent of patients was required 
for this study.
resuLts
In the late 1980s, there was a rapid increase in lifetime 
risk of being diagnosed with prostate cancer (figure 1). 
Although there was some increase in lifetime risk before 
the introduction of PSA testing to Australia in 1989, the 
steepest rise appears after 1989. The lifetime risk of being 
diagnosed with prostate cancer increased from 6.1% in 
1982 (1 in 17) to 18.4% in 1994 (1 in 6) (online supple-
mentary table 1). Using 2012 competing mortality rates 
for all years, the lifetime risks for all years were higher, but 
mirrored the changes described above. Adjusted lifetime 
risk increased from 11.5% (11.0%–12.0%) in 1982 (1 in 
9) to reach a peak of 24.8% (24.4%–25.4%) in 1994 (1 in 
4). The lifetime risk of prostate cancer has shown some 
fluctuations after this, but has never dipped below 15%, 
and in the most recent year (2012) was 19.7% (95% CI 
19.4% to 20.0%) (1 in 5).
The excess in adjusted lifetime risk of each index year 
compared with 1982 also parallels the temporal trends 
described above (figure 2). Once screening is estab-
lished in the population, the excess adjusted lifetime 
cancer risk represents potential overdiagnosis; in our 
example, we assumed establishment of screening in the 
Figure 1 Lifetime risk of prostate cancer diagnosis in 
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population from 20 years after introduction of PSA (ie, 
2009 onwards). The maximal estimated lifetime risk of 
overdiagnosis was around 12.2% (11.6%–12.8%) in 2009 
(one in nine men would have an overdiagnosed cancer 
in their lifetime) (online supplementary table 2). There 
was a subsequent decline in risk of overdiagnosis with an 
estimate in the most recent year (2012) of around 8.2% 
(7.6%–8.7%) (1 in 13 men overdiagnosed with cancer). 
Calculated as the proportion of cancers diagnosed over 
a lifetime in unscreened men, we estimate that 71% of 
prostate cancers may be overdiagnosed (8% lifetime risk 
of overdiagnosed cancer in 2012/11.5% adjusted lifetime 
risk of prostate cancer in 1982). Calculated as the propor-
tion of cancers diagnosed over a lifetime in screened men, 
we estimate that 41% of prostate cancers may be overdiag-
nosed (8% lifetime risk of overdiagnosed cancer/19.6% 
adjusted lifetime risk of prostate cancer in 2012).
Checking assumptions and sensitivity analysis using birth 
cohort data
To check the assumption that screening rates were estab-
lished, and the extent to which older men in recent years 
had previously been exposed to screening activities, we 
examined age-specific rates of PSA testing. Annual data 
on PSA testing were obtained from the MBS, which lists 
Medicare services subsidised by the Australian govern-
ment; specifically, we examined claims made for MBS 
item 66 655 (‘PSA used only for screening purposes’, data 
available only from 2001).25 Although these trends show 
some increases and decreases across all age groups, PSA 
screening appears to be well established in the popula-
tion by 2012 (online supplementary figure 1).
The assumption that screening is well established is 
necessary when using cross-sectional data to calculate 
excess lifetime risk. However, if birth cohort data are 
used instead, this assumption may be relaxed, as earlier 
exposure to screening will be accounted for in the 
observed incidence rates at younger ages for the cohort. 
In figure 3, we can see that there are some differences 
in the age-specific prostate cancer incidence for different 
birth cohorts, which is likely to reflect different exposures 
to PSA screening. As a supplement to our main analysis 
using cross-sectional data, we conducted a sensitivity anal-
ysis using the age-specific incidence and mortality data 
for two birth cohorts of men to calculate excess lifetime 
risk. The older birth cohorts were men born in 1912, 
and these men were mostly unexposed to PSA up to age 
80 years (PSA was first introduced into Australia when 
they were 79 years old). The younger birth cohorts were 
men born in 1932, and these men were exposed to PSA 
screening from approximately age 57 to 80 years. Where 
the relevant age-specific incidence, mortality or popula-
tion data were not available, we used available rates from 
years that were closest in time to the missing rates. As 
age-specific incidence rates were only available from 1982 
onwards, we had to use the same age-specific incidence 
rates for both birth cohorts up until age 70. We used the 
same age-specific mortality rates for both birth cohorts to 
allow for changes in competing risk; these were based on 
those for the 1932 birth cohort with rates (with age-spe-
cific rates from 1972 used for age <40 years, as this is the 
earliest data available).
The cumulative risk of a prostate cancer diagnosis by 
age 80 for men born in 1912, adjusted for mortality rates 
observed for the 1932 birth cohort, was 5.1%. The cumu-
lative risk of a prostate cancer diagnosis by age 80 for men 
born in 1932 was 8%, thus, there was an excess cumulative 
risk of 2.9%. This corresponds to an overdiagnosis rate of 
2.9/8.0=36.3%, as a proportion of cancers in a screened 
population—similar to our estimated overdiagnosis rate 
of 41% calculated using the cross-sectional data for 2012 
vs 1982.
From figure 3, we can see that the age-specific esti-
mates for the 1932 birth cohort (second most left-hand 
column) tend to be lower than the age-specific 2012 data 
used for the cross-sectional analysis (open circles). This 
is especially the case for men in the age groups under 
60 years who are largely unscreened in the 1932 birth 
cohort. Further, as noted above, because of missing data 
for age-specific incidence prior to 1982, we had to use the 
same rates both screened and unscreened cohorts up to 
age 70 and lifetime risk for the 1912 birth cohort is likely 
to have been overestimated. Therefore, our estimate 
of excess cumulative risk of a prostate cancer diagnosis 
using the 1932 vs 1912 birth cohorts is likely to underesti-
mate overdiagnosis for contemporary populations of men 
who are exposed to PSA testing from age 40 or younger.
Figure 2 Excess lifetime risk of diagnosis of prostate cancer 
in Australia from 1982 to 2012. Estimated excess lifetime 
risk of diagnosis=(adjusted lifetime risk of diagnosis in year 
after 1982—adjusted lifetime risk of diagnosis in 1982). To 
allow for the compensatory drop expected with the earlier 
detection of non-overdiagnosed cancers through screening, 
a sufficient time is needed after the introduction of screening 
before calculation of excess life risk of diagnosis provides a 
valid estimate of lifetime risk of overdiagnosis. For prostate 
cancer in Australia, the excess lifetime risk of prostate cancer 
for calendar years after 2009 (20 years after PSA introduced) 
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DIsCussIOn
Our estimate that 41% of screen-detected cancers are 
overdiagnosed is comparable to previously published 
estimates derived from data from follow-up reports after 
prostate cancer screening RCTs. The most recent estimate 
of overdiagnosis from the 13 years follow-up report of the 
European Randomised Study of Screening for Prostate 
Cancer was around 43% of screen-detected cancers26 while 
the previous estimates based on the same trial varied from 
50% to 67%.27–30 A recent review by United States Preven-
tive Services Task Force also reported that 20%–50% of 
screen-detected prostate cancers were overdiagnosed.19
Compared with the pre-PSA era, a number of factors 
are likely to have contributed to the excess incidence of 
prostate cancer observed following the introduction of 
PSA screening.31 32 These include: increased awareness of 
the disease, participation in screening activities, lowering 
of the histopathology threshold for diagnosis of cancer 
and interobserver disagreement on the histopathology 
diagnosis of cancer,33 34 and importantly discrepancy 
between a histopathology diagnosis of cancer and actual 
clinical significance/natural history of the lesion if left 
untreated.35 36 These factors help to explain how avail-
ability of PSA screening may result in overdiagnosis, but 
are not alternative hypotheses for the apparent overdi-
agnosis found in our results. The only alternative expla-
nation to overdiagnosis that is consistent with the data 
is a true change in clinically important prostate cancer 
incidence due to changes in risk factors over time, but 
such a large increase in underlying risk seems unlikely.
Challenges to the method
Using life tables based on annual (cross-sectional) data to 
calculate lifetime risk of cancer overdiagnosis has similar 
applicability issues for the hypothetical cohort as when 
using this method to calculate lifetime risk of cancer 
including the limitations that come with using aggregated 
population data. Additionally, it has the requirement that 
the data must capture potential benefits in later life of 
early cancer detection at a younger age. This means that 
screening needs to be established for a period at least as 
long as the average screening lead time of non-overdiag-
nosed cancers. This requirement may be relaxed where 
birth cohort (longitudinal) data are used, but there may 
often be an insufficiently long period of available data for 
accurate estimates, as was the case in our example. And 
regardless of whether annual or birth cohort data are 
used, we are still reliant on aggregated population data, 
and we do not know the lifetime screening experience of 
individual people.
The method also assumes that there are no important 
changes in risk factors for the cancer which would 
change the true age-specific incidence. While this may be 
reasonable for prostate cancer, it may not be for other 
cancers. For example, for lung cancer, we would need to 
consider changes in the rates of smoking over time, and 
Figure 3 Age-specific prostate cancer incidence by birth cohort from 1982 to 2012. Age-specific incidence rates of prostate 
cancer by midyear of birth cohort, Australia 1982–2012. The years of birth on the horizontal axes in figure 3 indicate the 
midpoints of non-overlapping 5-year birth cohorts (except for the period 1912–1932). The points vertically above each midpoint 
year show that cohort’s age-specific incidence rates (on the log scale). The data points corresponding to the incidence in 2012 
used for calculating overdiagnosis using cross-sectional data are indicated by an open circle at the right-hand side of each 
age-specific incidence trajectory. The single incidence data point (white circle with a black outline) for 80–84 age group in 1932 
birth year (741) overlaps very closely with the 70–74 age group incidence data point (dark blue) for 1932 (772) in the log scale. 
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the time lag we would expect for consequent changes in 
underlying (non-overdiagnosed) lung cancer rates to be 
observed. Development of an additional modelling step 
to the life table method may account for such underlying 
temporal changes in risk factors.
The introduction of new technologies or screening 
protocols (eg, greater number of prostate cores sampled 
with prostate biopsy after a positive PSA test result) could 
increase detection rates in more recent calendar years 
compared with previous years. If some of this is bene-
ficial detection of clinically significant cancers, then 
using cross-sectional data may overestimate the extent 
of overdiagnosis. Conversely, there is likely to have been 
overdiagnosed cancers included in the unscreened esti-
mates from 1982, due to incidental diagnosis of indolent 
cancers in Trans Urethral Resections of the Prostate and 
other surgical procedures, which would lead to an under-
estimation of overdiagnosis.
utility of the method
Despite some limitations, there are clear advantages to the 
life table method, especially the relaxation of the require-
ment that estimates must be adjusted for lead times of 
non-overdiagnosed cancers. The method is also relatively 
simple to apply using freely available statistical software 
and publicly available administrative datasets. It may be 
used to estimate the extent of overdiagnosis in popu-
lations where data from RCTs are not available. While 
we are not suggesting that this method should replace 
other methods, it may be used in combination with other 
methods to triangulate the likely extent of cancer overdi-
agnosis to produce a plausible upper and lower range of 
estimates, and to assess whether overdiagnosis is large or 
small.37
The analysis of long-term follow-up after screening 
RCTs remains the gold-standard method for estimating 
the effects of screening, both beneficial mortality reduc-
tion and overdiagnosis, but requires very long-term 
follow-up beyond the end of trial, and measurement of 
post-trial screening of participants which is currently not 
done. In the meantime, the life table method for esti-
mating lifetime risk of overdiagnosis described in this 
paper is a valuable addition to existing methods for esti-
mating overdiagnosis.
COnCLusIOn
Population data for cancer incidence, cancer mortality 
and all-cause mortality rates may be used to estimate 
the lifetime risk of cancer overdiagnosis using methods 
commonly employed to estimate the lifetime risk of cancer 
diagnosis. Using cross-sectional data, the method may 
give valid estimates in populations where screening has 
been established long enough for the benefits from the 
early detection of non-overdiagnosed cancer at a younger 
age to be realised in older age groups (established longer 
than the average lead time). Birth cohort data may also 
be used and may be increasingly informative as cohorts 
exposed to screening at a younger age are growing older. 
This novel method may usefully complement existing 
methods to estimate overdiagnosis.
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